Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in GPCR signalling are implicated in the pathogenesis and treatment of neuropsychiatric55, immunological56, gastrointestinal57,58, cardiac59, renal, hormonal, infectious60 and many other disorders53,54.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [55]
In the citing paper
“most clinically effective antipsychotics also exhibit a myriad of other actions that contribute to both therapeutic and side-effect profiles [359,360].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [360]
In the citing paper
“This often generates beneficial therapeutic activities,102 due to additive or synergistic pharmacological effects.103”
From QSAR without borders (2020) · cites this paper as [102]
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
(2003) · The Lancet · doi:10.1016/s0140-6736(03)12705-5 · Cited by 1,706
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia
Lewis, C. M., Levinson, D. F., Wise, L. H., DeLisi, L. E., Straub, R. E., Hovatta, I., Williams, N. M., Schwab, S. G., Pulver, A. E., Faraone, S. V., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/376549 · Cited by 1,137
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Self-citationBurris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Research works printed but not linked: 1
- Hemrick–Luecke, S. et al. Pharmacological activity of aripiprazole at presynaptic and postsynaptic dopamine receptors and in antipsychotic models. Proc. Soc. Neurosci. 894.9 (2002).
Cited by
Items 501–600 of 1,000
Molecular basis of human trace amine-associated receptor 1 activation
Zilberg, G., Parpounas, A. K., Warren, A. L., Yang, S., & Wacker, D. (2024) · Nature Communications · doi:10.1038/s41467-023-44601-4 · Cited by 33
Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders
Chen, Y., & Palczewski, K. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103033 · Cited by 33
Wu, Z., Lü, W., Yu, W., Wang, T., Li, W., Liu, G., Zhang, H., Pang, X., Huang, J. Y., Liu, M., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.005 · Cited by 31
Mechanisms of Action of Autophagy Modulators Dissected by Quantitative Systems Pharmacology Analysis
Shi, Q., Pei, F., Silverman, G. A., Pak, S. C., Perlmutter, D. H., Liu, B., & Bahar, İ. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082855 · Cited by 32
Corticosteroid-induced psychiatric disturbances: It is time for pharmacists to take notice
Kusljic, S., Manias, E., & Gogos, A. (2015) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2015.05.012 · Cited by 37
Cao, D., Zhang, P., & Wang, S. (2024) · Neuron · doi:10.1016/j.neuron.2024.01.004 · Cited by 33
Computational methods for early predictive safety assessment from biological and chemical data
Nigsch, F., Lounkine, E., McCarren, P. R., Cornett, B., Glick, M., Azzaoui, K., Urbán, L., Marc, P., Müller, A., Hahne, F., et al. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.632632 · Cited by 32
Multi-Target β-Protease Inhibitors from Andrographis paniculata: In Silico and In Vitro Studies
Panche, A. N., Chandra, S., & Diwan, A. (2019) · Plants · doi:10.3390/plants8070231 · Cited by 36
Protein wrapping: a molecular marker for association, aggregation and drug design
Fernández, A., & Crespo, A. (2008) · Chemical Society Reviews · doi:10.1039/b804150b · Cited by 33
Brain Metabolic Changes in Rats following Acoustic Trauma
He, J. B., Zhu, Y., Aa, J., Smith, P. F., Ridder, D. D., Wang, G., & Zheng, Y. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00148 · Cited by 30
Lago, S. G., Tomasik, J., van Rees, G. F., Steeb, H., Cox, D., Rustogi, N., Ramsey, J. M., Bishop, J. A., Petryshen, T. L., Haggarty, S. J., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau9093 · Cited by 31
Pharmacological treatment to augment hole board habituation in prenatal Vitamin D-deficient rats
Becker, A., & Grecksch, G. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.07.010 · Cited by 30
Developing New Drugs for Schizophrenia: From Animals to the Clinic
Jones, D. N. C., Gartlon, J. E., Minassian, A., Perry, W., & Geyer, M. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00008-4 · Cited by 34
Williams, M. J. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.08.019 · Cited by 34
Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats
Goudie, A. J., Cooper, G. D., Cole, J. C., & Sumnall, H. R. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881107067076 · Cited by 31
Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice
Moreno, J. L., Holloway, T. D., Umali, A., Rayannavar, V., Sealfon, S. C., & González‐Maeso, J. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2809-7 · Cited by 31
Drug Discovery and Delivery in the 21st Century
Triggle, D. J. (2006) · Medical Principles and Practice · doi:10.1159/000096133 · Cited by 31
Computational Polypharmacology Analysis of the Heat Shock Protein 90 Interactome
Anighoro, A., Stumpfe, D., Heikamp, K., Beebe, K. E., Neckers, L. Μ., Bajorath, J., & Rastelli, G. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci5006959 · Cited by 29
Phenotypic Assessment and the Discovery of Topiramate
Maryanoff, B. E. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00176 · Cited by 32
Kassan, A., Egawa, J., Zhang, Z., Almenar‐Queralt, A., Nguyen, Q. M., Lajevardi, Y., Kim, K., Posadas, E., Jeste, D. V., Roth, D. M., et al. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00481.2016 · Cited by 30
Development of functionally selective agonists as novel therapeutic agents
Berg, K. A., & Clarke, W. P. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.10.017 · Cited by 29
Deep phenotypic profiling of neuroactive drugs in larval zebrafish
Gendelev, L., Taylor, J. C., Myers-Turnbull, D., Chen, S., McCarroll, M. N., Arkin, M. R., Kokel, D., & Keiser, M. J. (2024) · Nature Communications · doi:10.1038/s41467-024-54375-y · Cited by 30
5-hydroxytryptamine subtype 6 receptor modulators: a patent survey
Ivachtchenko, A. V., Ivanenkov, Y. A., & Tkachenko, S. E. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.494661 · Cited by 28
Busquets-García, A., Maldonado, R. J., & Ozaita, A. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.05.004 · Cited by 34
Identifying Tinnitus‐Related Genes Based on a Side‐Effect Network Analysis
Elgoyhen, A. B., Langguth, B., Nowak, W., Schecklmann, M., Ridder, D. D., & Vanneste, S. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.75 · Cited by 30
Zagórska, A., Kołaczkowski, M., Bucki, A., Siwek, A., Kazek, G., Satała, G., Bojarski, A. J., Partyka, A., Wesołowska, A., & Pawłowski, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.046 · Cited by 30
Green, L. K., Zareie, P., Templeton, N., Keyzers, R. A., Connor, B. J., & Flamme, A. C. L. (2017) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217317698724 · Cited by 28
Nakamura, Y., Ishii, J., & Kondo, A. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25597 · Cited by 28
Chemogenetics for cell-type-specific modulation of signalling and neuronal activity
Kang, H. J., Minamimoto, T., Wess, J., & Roth, B. L. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00276-1 · Cited by 30
Self-citationLead optimization in the nondrug-like space
Zhao, H. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.12.002 · Cited by 27
Salomé, C., Salomé-Grosjean, E., Stables, J. P., & Kohn, H. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100185c · Cited by 28
Gostner, J. M., Wrulich, O. A., Jenny, M., Fuchs, D., & Ueberall, F. (2012) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-12-18 · Cited by 34
Brea, J. M., Castro, M., Loza, M. I., Masaguer, C. F., Raviña, E., Dezi, C., Pastor, M., Sanz, F., Cabrero-Castel, A., Galán-Rodríguez, B., et al. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.03.021 · Cited by 27
Selective disruption of dopamine D2-receptors/beta-arrestin2 signaling by mood stabilizers
Guidice, T. D., & Beaulieu, J. (2015) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2015.1072976 · Cited by 30
Kondej, M., Wróbel, T. M., Silva, A., Stępnicki, P., Koszła, O., Kędzierska, E., Bartyzel, A., Biała, G., Matosiuk, D., Loza, M. I., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.050 · Cited by 27
Calarge, C. A., Burns, T. L., Schlechte, J., & Zemel, B. S. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09195 · Cited by 27
Bacterial proteins and CpG-rich extrachromosomal DNA in potential cancer therapy
Mahfouz, M. M., Hashimoto, W., Gupta, T. K. D., & Chakrabarty, A. M. (2006) · Plasmid · doi:10.1016/j.plasmid.2006.11.001 · Cited by 27
Paul, N. M., Taylor, M., Kumar, R., Deschamps, J. R., Luedtke, R. R., & Newman, A. H. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800532x · Cited by 31
Muscarinic Receptors in Psychiatric Disorders – Can We Mimic ‘Health’?
Scarr, E. (2009) · Neurosignals · doi:10.1159/000231896 · Cited by 28
Nigratine as dual inhibitor of necroptosis and ferroptosis regulated cell death
Delehouzé, C., Comte, A., Leon‐Icaza, S. A., Cougoule, C., Hauteville, M., Goekjian, P. G., Bulinski, J. C., Dimanche‐Boitrel, M., Meunier, É., Rousselot, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09019-w · Cited by 26
Ivachtchenko, A. V., Frolov, E. B., Mitkin, O. D., Tkachenko, S. E., Okun, I. M., & Khvat, A. V. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.037 · Cited by 29
Antipsychotic agents: efficacy and safety in schizophrenia
de Sena, E. P., Araújo, de Oliveira, I., & Juruena, M. F. (2012) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s37429 · Cited by 34
Sakuma, K., Komatsu, H., Maruyama, M., Imaichi, S., Habata, Y., & Mori, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118510 · Cited by 27
Insights from systems pharmacology into cardiovascular drug discovery and therapy
Li, P., Fu, Y., Ru, J., Huang, C., Du, J., Zheng, C., Chen, X., Li, P., Lü, A., Yang, L., et al. (2014) · BMC Systems Biology · doi:10.1186/s12918-014-0141-z · Cited by 26
Meleddu, R., Cannas, V., Distinto, S., Sarais, G., Vecchio, C. D., Esposito, F., Bianco, G., Corona, A., Cottiglia, F., Alcaro, S., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201402015 · Cited by 26
Intermodule Coupling Analysis of Huang-Lian-Jie-Du Decoction on Stroke
Wang, P., Li, D., Zhou, W., Meng, J., Zhang, M., Wu, Y., Huo, H.-R., Xiong, X., & Sui, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01288 · Cited by 26
Impact of Different Antidopaminergic Mechanisms on the Dopaminergic Control of Prolactin Secretion
Veselinović, T., Schorn, H., Vernaleken, I., Schiffl, K., Klomp, M., & Gründer, G. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820e4832 · Cited by 30
Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder
Gray, L. J., Scarr, E., & Dean, B. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.09.010 · Cited by 26
Linck, V. M., Costa-Campos, L., Pilz, L. K., Garcia, C. R. L., & Elisabetsky, E. (2012) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283512c3a · Cited by 34
The Endocannabinoid System: An Osteopathic Perspective
McPartland, J. M. (2008) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2008.108.10.586 · Cited by 33
Structure‐Guided Design of G‐Protein‐Coupled Receptor Polypharmacology
Kampen, S., Vo, D. D., Zhang, X., Panel, N., Yang, Y., Jaiteh, M., Matricon, P. G., Svenningsson, P., Brea, J. M., Loza, M. I., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202101478 · Cited by 26
Jiao, S., Cao, T., & Cai, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1005702 · Cited by 29
Singh, R., Jia, C., Garcia, F., Carrasco, G. A., Battaglia, G., & Muma, N. A. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103090 · Cited by 25
Pompeu, T. E. T., Alves, F. R. S., Figueiredo, C. D. M., Antonio, C. B., Herzfeldt, V., Moura, B. C., Rates, S. M. K., Barreiro, E. J., Fraga, C. A. M., & Noël, F. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.05.027 · Cited by 26
Bardgett, M. E., Points, M., Roflow, J., Blankenship, M. L., & Griffith, M. S. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1566-8 · Cited by 25
Off-Target Networks Derived from Ligand Set Similarity
Keiser, M. J., & Hert, J. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-274-2_8 · Cited by 28
To Bind or Not to Bind: Unravelling GPCR Polypharmacology
Sexton, P. M., & Christopoulos, A. (2018) · Cell · doi:10.1016/j.cell.2018.01.018 · Cited by 25
Wang, P., Liu, Q., Xu, W., Yu, Y., Zhang, Y., Li, B., Liu, J. H., & Wang, Z. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.145 · Cited by 25
Cloud-Based High Throughput Virtual Screening in Novel Drug Discovery
Olğaç, A., Türe, A., Olğaç, S., & Möller, S. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-16272-6_9 · Cited by 28
Pinzi, L., & Rastelli, G. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00821 · Cited by 27
Nakaya, K., Nakagawasai, O., Arai, Y., Onogi, H., Sato, A., Niijima, F., Tan–No, K., & Tadano, T. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.053 · Cited by 26
Antipsychotic‐induced gene regulation in multiple brain regions
Girgenti, M. J., Nisenbaum, L. K., Bymaster, F. P., Terwilliger, R. Z., Duman, R. S., & Newton, S. S. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06585.x · Cited by 27
Designed multiple ligands in metabolic disease research: from concept to platform
Gattrell, W. T., Johnstone, C., Patel, S., Smith, C. S., Scheel, A. A., & Schindler, M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.02.006 · Cited by 25
When analoging is not enough: scaffold discovery in medicinal chemistry
Zhao, H., & Akritopoulou‐Zanze, I. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903584874 · Cited by 25
Choy, K. H. C., Shackleford, D. M., Malone, D. T., Mistry, S. N., Patil, R. T., Scammells, P. J., Langmead, C. J., Pantelis, C., Sexton, P. M., Lane, J. R., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235788 · Cited by 28
Koychev, I., Barkus, E., Ettinger, U., Killcross, S., Roiser, J. P., Wilkinson, L., & Deakin, B. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111414450 · Cited by 24
“putatively implicated in the pathogenesis of schizophrenia (Roth et al., 2004).”
BackgroundInfluentialChemical probes for biological systems
García-Serna, R., & Mestres, J. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.11.004 · Cited by 26
Cluster Analysis of Medicinal Plants and Targets Based on Multipartite Network
Lee, N., Yoo, H., & Yang, H. (2021) · Biomolecules · doi:10.3390/biom11040546 · Cited by 25
Gene expression changes following chronic antipsychotic exposure in single cells from mouse striatum
Abrantes, A., Giusti‐Rodríguez, P., Ancalade, N., Sekle, S., Basiri, M. L., Stuber, G. D., Sullivan, P. F., & Hultman, R. C. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01509-7 · Cited by 25
Systems Biology and Pharmacology
Berg, J. M., Rogers, M. E., & Lyster, P. M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.69 · Cited by 24
Johnson, D. S., Choi, C., Fay, L. K., Favor, D. A., Repine, J. T., White, A. D., Akunne, H. C., Fitzgerald, L. W., Nicholls, K., Snyder, B. J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.059 · Cited by 24
Todorović, N., & Filipović, D. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.04.044 · Cited by 25
D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine
Shen, Y., McCorvy, J. D., Martini, M. L., Rodriguiz, R. M., Pogorelov, V. M., Ward, K. M., Wetsel, W. C., Liu, J., Roth, B. L., & Jin, J. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00508 · Cited by 27
Self-citationAmada, N., Akazawa, H., Ohgi, Y., Maeda, K., Sugino, H., Kurahashi, N., Kikuchi, T., & Futamura, T. (2019) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12076 · Cited by 24
Brexpiprazole blocks post-traumatic stress disorder-like memory while promoting normal fear memory
Ducourneau, E., Guette, C., Perrot, D., Mondésir, M., Mombereau, C., Arnt, J., Desmedt, A., & Piazza, P. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0852-z · Cited by 25
González, J. B., el Jaber-Vazdekis, N., García-Expósito, L., Machado, J. D., Zárate, R., Ravelo, Á. G., Estévez‐Braun, A., & Valenzuela-Fernández, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.005835 · Cited by 27
1-Aminoindanes as novel motif with potential atypical antipsychotic properties
Graham, J. M., Coughenour, L. L., Barr, B. M., Rock, D. L., & Nikam, S. S. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.106 · Cited by 24
iPHACE: integrative navigation in pharmacological space
García-Serna, R., Ursu, O., Oprea, T. I., & Mestres, J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq061 · Cited by 26
Li, N., Cao, T., Wu, X., Tang, M., Xiang, D., & Cai, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01669 · Cited by 26
Diverse array-designed modes of combination therapies in Fangjiomics
Liu, J. H., & Wang, Z. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.125 · Cited by 23
Promiscuous modulation of ion channels by anti-psychotic and anti-dementia medications
Bianchi, M. T. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.09.003 · Cited by 26
Zagórska, A., Bucki, A., Kołaczkowski, M., Siwek, A., Głuch‐Lutwin, M., Starowicz, G., Kazek, G., Partyka, A., Wesołowska, A., Słoczyńska, K., et al. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1198902 · Cited by 23
Lee, K. H., Fant, A. D., Guo, J., Guan, A., Jung, J., Kudaibergenova, M., Miranda, W. E., Ku, T. C., Cao, J., Wacker, S., et al. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00856 · Cited by 24
Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia
Lago, S. G., & Bahn, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00205 · Cited by 25
Multiple binding sites in the nicotinic acetylcholine receptors: An opportunity for polypharmacolgy
Iturriaga‐Vásquez, P., Alzate‐Morales, J. H., Bermúdez, I., Varas, R., & Reyes-Parada, M. I. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.08.018 · Cited by 23
Allosteric Antipsychotics: M4 Muscarinic Potentiators as Novel Treatments for Schizophrenia
Farrell, M. S., & Roth, B. L. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.206 · Cited by 22
Self-citationPredicting targets of compounds against neurological diseases using cheminformatic methodology
Nikolic, K. M., Mavridis, L., Bautista‐Aguilera, Ó. M., Marco‐Contelles, J., Stark, H., Carreiras, M. C., Rossi, I., Massarelli, P., Agbaba, D. D., Ramsay, R. R., et al. (2014) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-014-9816-1 · Cited by 22
Ye, F. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1020788 · Cited by 22
Issa, N. T., Peters, O. J., Byers, S. W., & Dakshanamurthy, S. (2015) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207318666150803130138 · Cited by 25
Defining clinical outcome pathways
Korn, D., Thieme, A., Alves, V. M., Yeakey, M., Borba, J. V. V. B., Capuzzi, S. J., Fecho, K., Bizon, C., Edwards, S. W., Chirkova, R. Y., et al. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.008 · Cited by 25
Two new phenylpiperazines with atypical antipsychotic potential
Tomić, M., Ignjatović, Đ., Tovilović-Kovačević, G., Andrić, D. B., Roglić, G., & Kostić‐Rajačić, S. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.08.066 · Cited by 22
Selent, J., Martí-Solano, M., Rodríguez, J. O., V, Atanes, P., Brea, J. M., Castro, M., Sanz, F., Loza, M. I., & Pastor, M. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.02.058 · Cited by 22
Kim, E. Y., Chang, S. M., Shim, J. C., Joo, E.-J., Kim, J., Kim, Y. S., & Ahn, Y. M. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.816277 · Cited by 22
Graz, B., Falquet, J., & Elisabetsky, E. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.04.044 · Cited by 23
Compound Properties and their Influence on Drug Quality
Chen, H., Engkvist, O., & Kogej, T. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00015-8 · Cited by 26
Millan, M. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00001-1 · Cited by 23
Does consumer demand pull scientifically novel drug innovation?
Dranove, D., Garthwaite, C., & Hermosilla, M. (2022) · The RAND Journal of Economics · doi:10.1111/1756-2171.12422 · Cited by 28
G Protein β2 Subunit-derived Peptides for Inhibition and Induction of G Protein Pathways
Li, X., Hümmer, A., Han, J., Xie, M., Melnik-Martínez, K. V., Moreno, R. L., Buck, M., Mark, M. D., & Herlitze, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414078200 · Cited by 21
Chu, H., Yang, Z., Zhao, B., Jin, G.-Z., Hu, G., & Zhen, X. (2010) · Brain Research · doi:10.1016/j.brainres.2010.04.043 · Cited by 22
Park, K. D., Kim, D., Reamtong, O., Eyers, C. E., Gaskell, S. J., Liu, R., & Kohn, H. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2034156 · Cited by 21
Metadata
- Authors
- Roth, B. L., Sheffler, D. J., & Kroeze, W. K.
- Affiliations
- Case Western Reserve University (US)
- Corresponding author
- Roth, Bryan L.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 353-359
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2122995608
- Cited by
- 1,155
- References
- 63
- Citations by year
- 2026: 29 · 2025: 28 · 2024: 37 · 2023: 39 · 2022: 47 · 2021: 49 · 2020: 49 · 2019: 63 · 2018: 46 · 2017: 42 · 2016: 61 · 2015: 65 · 2014: 58 · 2013: 73 · 2012: 83
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- magic bullet, polygenic disease, mood disorders, schizophrenia, depression, bipolar disorder, central nervous system disorders, drug target selectivity, polypharmacology, antipsychotic drug development
- MeSH terms
- Humans, Schizophrenia, Antipsychotic Agents, Drugs, Investigational, Comorbidity, Mood Disorders, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.